Loading…
Teva Pharmaceuticals and Insilico Biotechnology announced an agreement to apply Insilico's predictive biomanufacturing technology (Digital Twins) to create more efficient production processes for Teva's biopharmaceutical therapeutics.
The Cooper Companies has entered into a definitive agreement to acquire the global rights and business of Teva's PARAGARD Intrauterine Device for $1.1 billion in cash. The deal includes Teva's manufacturing facility in Buffalo, NY.